Sign in

    William Sanger

    Research Analyst at Leerink Partners

    William Sanger is an Equity Research Analyst at Leerink Partners, specializing in life sciences and biotechnology coverage with a particular focus on innovative gene-editing companies. He has provided research coverage for companies such as Intellia Therapeutics, contributing to sector insights through targeted earnings call participation. Sanger's recent career at Leerink Partners began in the early 2020s, with limited publicly available history of prior firms. He holds relevant industry credentials, maintaining securities licensing required for research analysts at a registered broker-dealer.

    William Sanger's questions to Intellia Therapeutics (NTLA) leadership

    William Sanger's questions to Intellia Therapeutics (NTLA) leadership • Q1 2025

    Question

    William Sanger, on behalf of Mani Faroohar, asked for more detail on expected cash burn and operating expenses over the next 12-24 months, particularly regarding any notable non-recurring costs from the recent restructuring.

    Answer

    Chief Financial Officer Ed Dulac projected an average quarterly cash use of approximately $95 million for 2025 and 2026. He explained that Q1 2025 cash use was higher due to $51 million in non-recurring costs for severance and real estate transactions, which he noted are part of a cash-neutral plan expected to yield nearly $50 million in future savings. The current cash runway is sufficient into the first half of 2027.

    Ask Fintool Equity Research AI